Primary and Metastatic Intracranial Ewing Sarcoma at Diagnosis: Retrospective International Study and Systematic Review.

Ewing sarcoma intracranial metastatic outcome

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
24 Jun 2020
Historique:
received: 29 05 2020
revised: 21 06 2020
accepted: 22 06 2020
entrez: 1 7 2020
pubmed: 1 7 2020
medline: 1 7 2020
Statut: epublish

Résumé

Intracranial Ewing sarcoma (EwS) is rare and publications on primary or metastatic intracranial EwS are minimal. The aim of this study was to describe incidence, clinical behavior, treatment, and factors associated with outcome in patients with primary intracranial EwS or patients with a primary extracranial EwS and cerebral metastases at diagnosis. We reviewed all patients with primary or with metastatic intracranial EwS at diagnosis registered in the International Clinical Trial Euro-E.W.I.N.G.99 (EE99). In total, 17 of 1435 patients (1.2%) presented with primary intracranial EwS; 3 of them had metastatic disease. Four patients (0.3%) with primary extracranial EwS presented with intracranial metastatic lesions. The 3-year event-free survival (EFS) was 64% and overall survival (OS) was 70% in patients with a primary intracranial EwS. Local control in patients with primary intracranial EwS consisted of surgery (6%), radiotherapy (RT) (18%), or both modalities (76%). Univariate analysis showed that patients < 15 years of age had significantly better outcome (EFS: 72%; OS: 76%) compared to those aged above 15 years (EFS: 13%; OS: 25%). In conclusion, primary intracranial EwS and extracranial EwS with cerebral metastases at diagnosis is rare, yet survival is comparable with local and metastatic EwS elsewhere in the body. Age and stage of disease are important prognostic factors. Besides chemotherapeutic treatment, local control with surgical resection combined with RT is recommended whenever feasible.

Identifiants

pubmed: 32599807
pii: cancers12061675
doi: 10.3390/cancers12061675
pmc: PMC7352789
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : Deutsche Krebshilfe (DKH)
ID : 108128

Références

J Clin Oncol. 2010 Jul 10;28(20):3284-91
pubmed: 20547982
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
World Neurosurg. 2019 Feb;122:e1606-e1614
pubmed: 30496933
J Clin Oncol. 2000 Sep;18(17):3108-14
pubmed: 10963639
Surg Pathol Clin. 2017 Sep;10(3):575-585
pubmed: 28797503
Pediatr Blood Cancer. 2006 Jul;47(1):22-9
pubmed: 16572419
Am J Otolaryngol. 2013 Sep-Oct;34(5):563-8
pubmed: 23706594
Diagn Mol Pathol. 1993 Sep;2(3):141-6
pubmed: 8287228
J Neurooncol. 2011 Sep;104(3):629-38
pubmed: 21400119
Br J Radiol. 2014 Sep;87(1041):20130631
pubmed: 24988215
World Neurosurg. 2018 Jul;115:346-356
pubmed: 29729469
Cancer. 1982 Jun 1;49(11):2404-9
pubmed: 7074552
Cancer Chemother Pharmacol. 2011 Jan;67(1):27-33
pubmed: 20182727
J Neurol Sci. 2009 Sep 15;284(1-2):186-9
pubmed: 19394051
Diagn Mol Pathol. 2007 Jun;16(2):108-11
pubmed: 17525681
Pediatr Blood Cancer. 2005 Nov;45(6):850-6
pubmed: 15929128
Nat Rev Dis Primers. 2018 Jul 5;4(1):5
pubmed: 29977059
J Pharmacol Exp Ther. 2001 Jan;296(1):124-31
pubmed: 11123372
J Pediatr Orthop. 2008 Jan-Feb;28(1):29-35
pubmed: 18157043
J Pediatr Hematol Oncol. 1999 Sep-Oct;21(5):370-7
pubmed: 10524449
Pediatr Blood Cancer. 2016 Apr;63(4):604-10
pubmed: 26702872
Neurology. 1998 Nov;51(5):1336-8
pubmed: 9818856
Cancer Chemother Pharmacol. 1992;29(5):339-42
pubmed: 1312906
Childs Nerv Syst. 2018 Mar;34(3):441-448
pubmed: 29285586
Int J Clin Exp Pathol. 2015 Jan 01;8(1):260-74
pubmed: 25755713
Acta Oncol. 2006;45(4):469-75
pubmed: 16760184
Asian J Neurosurg. 2018 Apr-Jun;13(2):288-296
pubmed: 29682023
World Neurosurg. 2017 Feb;98:869.e1-869.e5
pubmed: 28017744
Asian J Neurosurg. 2017 Jul-Sep;12(3):351-357
pubmed: 28761507
J Clin Neurosci. 2012 Feb;19(2):203-9
pubmed: 22024233
Acta Neurochir (Wien). 1991;113(1-2):48-51
pubmed: 1799143
J Pediatr Neurosci. 2018 Oct-Dec;13(4):392-397
pubmed: 30937078
Clin Cancer Res. 1997 Nov;3(11):1985-92
pubmed: 9815588
Neuropathology. 2017 Feb;37(1):35-44
pubmed: 27500883
Cancer. 2002 Mar 15;94(6):1815-20
pubmed: 11920545

Auteurs

Lianne M Haveman (LM)

Princess Maxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

Andreas Ranft (A)

Department of Pediatric Hematology and Oncology, University Children's Hospital of Essen, Center of Pediatric Oncology. 45122 Essen, Germany.

Henk van den Berg (HVD)

Department of Pediatric Oncology, Academic Medical Center, Emma Children's Hospital, 1105 AZ Amsterdam, The Netherlands.

Stephanie Klco-Brosius (S)

Department of Pediatric Hematology and Oncology, University Children's Hospital of Essen, Center of Pediatric Oncology. 45122 Essen, Germany.

Ruth Ladenstein (R)

Children's Cancer Research Institute, 1090 Vienna, Austria.

Michael Paulussen (M)

Vestische Kinder- und Jugendklinik, Witten/Herdecke University, 45711 Datteln, Germany.

Heribert Juergens (H)

Department of Pediatric Hematology and Oncology, University Children's Hospital, 48149 Muenster, Germany.

Uta Dirksen (U)

Department of Pediatric Hematology and Oncology, University Children's Hospital of Essen, Center of Pediatric Oncology. 45122 Essen, Germany.

Johannes H M Merks (JHM)

Princess Maxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

Classifications MeSH